Discovery of novel anti-angiogenesis agents. Part 11: Development of PROTACs based on active molecules with potency of promoting vascular normalization

  • Yuanyuan Shan
  • , Ru Si
  • , Jin Wang
  • , Qingqing Zhang
  • , Jing Li
  • , Yuexiang Ma
  • , Jie Zhang

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Our recent investigation is focused on the discovery of anti-angiogenesis agents. Vascular normalization induced by anti-angiogenic agent appears to be a promising strategy. We have developed novel angiogenesis inhibitors with potency of promoting vascular normalization. Herein, we reported the design, synthesis and preliminary evaluation of proteolysis-targeting chimera (PROTACs) based on the previously developed anti-angiogenesis agents. Two PROTACs exhibited potent VEGFR-2 inhibition and anti-proliferative activity against HUVECs. Moreover, they were capable of reducing protein levels of VEGFR-2 in EA.hy926 cells without significant cytotoxicity against HEK293 cells. The novel PROTACs could be used to normalize the abnormal vessels, resulting in efficient delivery of drugs.

Original languageEnglish
Article number112654
JournalEuropean Journal of Medicinal Chemistry
Volume205
DOIs
StatePublished - 1 Nov 2020

Keywords

  • Active molecules
  • Anti-angiogenesis agents
  • PROTACs
  • Vascular normalization

Fingerprint

Dive into the research topics of 'Discovery of novel anti-angiogenesis agents. Part 11: Development of PROTACs based on active molecules with potency of promoting vascular normalization'. Together they form a unique fingerprint.

Cite this